{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:05:16Z","timestamp":1775862316795,"version":"3.50.1"},"reference-count":57,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicines"],"abstract":"<jats:p>Background: Polymyalgia Rheumatica (PMR) is one of the most frequent rheumatologic immune-related adverse effects (IRAEs) in cancer patients following therapy with immune checkpoint inhibitors (ICIs). Atypical findings in many patients often lead to diagnosing PMR-like syndromes. Materials and methods: The aim of our research was to review reported diagnoses of PMR and PMR-like syndromes following ICIs therapy, and assess whether they can be redefined as adverse drug reaction (ADR). In line with PRISMA guidelines, we carried out a systematic search on three main bibliographic databases, based on a combination of subject headings and free text. We included all studies and case-reports published after 2011 (when FDA approved the use of the first ICI) describing the association of PMR or PMR-like syndromes with all types of ICIs therapy. We excluded reviews, conference abstracts, comments, secondary articles, and non-English language studies. Results: We reviewed data from seven studies and eight case-reports, involving a total of 54 patients. Limitations included: the small size of all studies; only one retrospective study used validated criteria for PMR; most reports assessed IRAEs by clinical judgment only and did not seek validation through assessment scales. To date, it remains a conundrum whether IRAEs-PMR is identical to the idiopathic form of the disease, or whether it should be considered a subset of the disease or a new entity. Conclusions: Our review indicates that the relationship between PMR and ICIs therapy is yet to be clearly understood and defined and that future research should remedy the current limits in study design.<\/jats:p>","DOI":"10.3390\/medicines7110068","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T09:09:32Z","timestamp":1604394572000},"page":"68","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Identification and Classification of Polymyalgia Rheumatica (PMR) and PMR-Like Syndromes Following Immune Checkpoint Inhibitors (ICIs) Therapy: Discussion Points and Grey Areas Emerging from a Systematic Review of Published Literature"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4800-1817","authenticated-orcid":false,"given":"Ciro","family":"Manzo","sequence":"first","affiliation":[{"name":"Azienda Sanitaria Locale Napoli 3 sud, Internal and Geriatric Medicine Department, Rheumatologic Outpatient Clinic, Health District No. 59, 80065 Sant\u2019Agnello (Naples), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Isetta","sequence":"additional","affiliation":[{"name":"Library and Knowldege Services, Central and North West London NHS Foundation Trust, London NW1 3AX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Natale","sequence":"additional","affiliation":[{"name":"Azienda Sanitaria Locale Napoli 3 sud, Internal and Geriatric Medicine Department, Rheumatologic Outpatient Clinic, Health District No. 58, 80054 Gragnano (Naples), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-2055","authenticated-orcid":false,"given":"Alberto","family":"Castagna","sequence":"additional","affiliation":[{"name":"Geriatric Medicine Department Azienda Sanitaria Provinciale Catanzaro, Fragility Outpatient Clinic, Casa Della Salute di Chiaravalle Centrale, Chiaravalle, 88100 Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","article-title":"Epidemiology of polymyalgia rheumatica 2000\u20132014 and examination of incidence and survival trends over 45 years: A population-based study","volume":"69","author":"Raheel","year":"2017","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"ref_2","first-page":"S9","article-title":"Epidemiology of polymyalgia rheumatica","volume":"18","author":"Cimmino","year":"2000","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Manzo, C. (2019). Incidence and prevalence of polymyalgia rheumatica (PMR): The importance of the epidemiological context. The Italian case. Med. Sci., 7.","DOI":"10.3390\/medsci7090092"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Martin","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/annrheumdis-2018-213883","article-title":"Incidence, Prevalence and Treatment Burden of Polymyalgia Rheumatica in the UK Over Two Decades: A Population-Based Study","volume":"77","author":"Partington","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4081\/reumatismo.2018.1036","article-title":"The role of general practictioner and out-of-hospital public rheumatologist in the diagnosis and follow-up of the patient with polymyalgia rheumatica","volume":"70","author":"Sobrero","year":"2018","journal-title":"Reumatismo"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Manzo, C. (2018). Polymyalgia rheumatica (PMR) with normal values of both erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) concentration at the time of diagnosis in a centenarian man: A case report. Diseases, 6.","DOI":"10.3390\/diseases6040084"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","article-title":"Polymyalgia rheumatica","volume":"390","author":"Matteson","year":"2017","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"ITC65","DOI":"10.7326\/AITC201705020","article-title":"Polymyalgia rheumatica","volume":"166","author":"Matteson","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_10","first-page":"593","article-title":"Diagnosis of polymyalgia rheumatica usually means a favourable outcome for your patient","volume":"145","author":"Milchert","year":"2017","journal-title":"Indian J. Med. Res."},{"key":"ref_11","first-page":"221","article-title":"La polimialgia reumatica: Difficolt\u00e0 diagnostiche e terapeutiche per una malattia apparentemente \u201cbanale\u201d","volume":"108","author":"Manzo","year":"2017","journal-title":"Recenti Progress. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/reum.2018.74740","article-title":"Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis: A four-point guidance","volume":"56","author":"Manzo","year":"2018","journal-title":"Reumatologia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/rheumatology\/key431","article-title":"Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis","volume":"5","author":"Manzo","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.34356","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"64","author":"Dasgupta","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/ard.2004.025296","article-title":"A comparison of sensitivity of diagnostic criteria for polymyalgia rheumatica","volume":"64","author":"Bird","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2011.09.002","article-title":"Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer","volume":"65","author":"Graziani","year":"2012","journal-title":"Pharmacol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: From mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12531","article-title":"Introduction to checkpoint inhibitors and cancer immunotherapy","volume":"276","author":"Sharpe","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_19","unstructured":"(2020, June 12). Timeline of Progress in Immunotherapy\u2013Cancer Research Institute. Available online: https:\/\/www.canceresearch.org\/immunotherapy\/timeline-of-progress."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis","volume":"82","author":"Champiat","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2019-0083","article-title":"Diagnosis and Management of Rare Immune-Related Adverse Events","volume":"25","author":"Schoenfeld","year":"2020","journal-title":"Oncologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitory therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: A single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/1573397115666190119094736","article-title":"Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Shoul Know?","volume":"15","author":"Gediz","year":"2019","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: Current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of non-randomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"ref_32","unstructured":"Higgins, J.P.T., and Green, S. (2020, August 26). Cochrane Handbook for Systematic Reviews of Interventions. Available online: http:\/\/handbook.cochrane.org."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CJI.0000000000000163","article-title":"Nivolumab Causing a Polymyalgia Rheumatica in a Patient with a Squamous Non-Small Cell Lung Cancer","volume":"40","author":"Bernier","year":"2017","journal-title":"J Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1136\/annrheumdis-2018-213672","article-title":"Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK \u00bd inhibitor","volume":"78","author":"Chan","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1248\/yakushi.18-00161","article-title":"Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment","volume":"139","author":"Imai","year":"2019","journal-title":"J. Pharm. Soc. Jpn."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jbspin.2016.01.007","article-title":"Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma","volume":"84","author":"Garel","year":"2017","journal-title":"Jt. Bone Spine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1177\/1078155218800386","article-title":"Polymyalgia rheumatica due to pembrolizumab therapy","volume":"25","author":"Iskandar","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00432-017-2410-x","article-title":"Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment","volume":"143","author":"Nakamagoe","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_39","first-page":"413","article-title":"Polymyalgia rheumatic occurring during treatment with ipilimumab","volume":"26","author":"Maniu","year":"2016","journal-title":"Eur. J. Derm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"E000906","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: Case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: A single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kostine, M., Finckh, A., Bingham, C.O., Visser, K., Leipe, J., Schulze-Koops, H., Choy, E.H., Benesova, C., Radstake, T.R.D.J., and Cope, A.P. (2020). EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann. Rheum. Dis., 1\u201313.","DOI":"10.1136\/annrheumdis-2020-217139"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritris and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2017.10.018","article-title":"Rheumatologic symptoms in oncologic patients on PD-1 inhibitors","volume":"47","author":"Kuswanto","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4081\/reumatismo.2018.1048","article-title":"Pathogenesis of polymyalgia rheumatica","volume":"70","author":"Guggino","year":"2018","journal-title":"Reumatismo"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3899\/jrheum.160232","article-title":"Are the new ACR\/EULAR criteria the ultimate answer for polymyalgia rheumatica classification?","volume":"43","author":"Camellino","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1756-185X.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy","volume":"22","author":"Liew","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5114\/reum.2020.96549","article-title":"Polymyalgia rheumatica with normal inflammatory indices at the time of diagnosis: Can we just move a step forward?","volume":"58","author":"Manzo","year":"2020","journal-title":"Reumatologia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","article-title":"Methods for causality assessment of adverse drug reactions","volume":"31","author":"Agbabiaka","year":"2008","journal-title":"Drug Saf."},{"key":"ref_54","first-page":"606","article-title":"Adverse drug reaction\u2013Causality assessment","volume":"1","author":"Srinivasan","year":"2011","journal-title":"Int. J. Res. Pharm. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reaction","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_56","first-page":"1162","article-title":"Challenges faced when identifying patients for combination immunotherapy","volume":"153","author":"Ernstoff","year":"2017","journal-title":"Future Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (dire) after discontinuation of immunotherapy: Diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Coury","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6320\/7\/11\/68\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:28:25Z","timestamp":1760178505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6320\/7\/11\/68"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["medicines7110068"],"URL":"https:\/\/doi.org\/10.3390\/medicines7110068","relation":{},"ISSN":["2305-6320"],"issn-type":[{"value":"2305-6320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]}}}